Comparing three screening tools for drug-induced parkinsonism in patients with advanced schizophrenia: A pilot study

Schizophrenia Research

Volumn 137, Issue 1-3, 2012, Pages 230-233

  Blanchet, Pierre J ^a,b,c   Normandeau, Louise ^c   Rompré, Pierre H ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

Author keywords

Antipsychotic drugs; Drug induced parkinsonism; Parkinson's disease; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; COMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG INDUCED PARKINSONISM; FEMALE; HEALTH SURVEY; HUMAN; LIVERPOOL UNIVERSITY NEUROLEPTIC SIDE EFFECTS RATING SCALE; MAJOR CLINICAL STUDY; MALE; PARKINSONISM; PILOT STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; QUESTIONNAIRE; SCHIZOPHRENIA; SCREENING; SENSITIVITY AND SPECIFICITY; UNIFIED PARKINSON DISEASE RATING SCALE; VALIDATION PROCESS;

AGED; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PARKINSON DISEASE, SECONDARY; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; QUESTIONNAIRES; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 84860833466     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.01.013     Document Type: Article

References (25)

1. Altman D.G., Bland J.M. Diagnostic tests 2: predictive values. B.M.J. 1994, 309(6947):102.
2. Burn D.J., Brooks D.J. Nigral dysfunction in drug-induced parkinsonism: an 18F-dopa study. Neurology 1993, 43:552-556.
3. Caligiuri M.P., Teulings H.-L., Filoteo J.V., Song D., Lohr J.B. Quantitative measurement of handwriting in the assessment of drug-induced parkinsonism. Hum. Mov. Sci. 2006, 25:510-522.
4. Chan D.K.Y., Hung W.T., Wong A., Hu E., Beran R.G. Validating a screening questionnaire for parkinsonism in Australia. J. Neurol. Neurosurg. Psychiatry 2000, 69:117-120.
5. Cunningham Owens D.G. Parkinsonism. A Guide to the Extrapyramidal Side-effects of Antipsychotic Drugs 1999, 68-129. Cambridge University Press, Cambridge.
6. Day J.C., Wood G., Dewey M., Bentall R.P. A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br. J. Psychiatry 1995, 166:650-653.
7. Duarte J., Clavería L.E., De Pedro-Cuesta J., Sempere A.P., Coria F., Calne D.B. Screening Parkinson's disease: a validated questionnaire of high specificity and sensitivity. Mov. Disord. 1995, 10:643-649.
8. Emsley R., Niehaus D.J.H., Oosthuizen P.P., Koen L., Chiliza B., Fincham D. Subjective awareness of tardive dyskinesia and insight in schizophrenia. Eur. Psychiatry 2011, 26:293-296.
9. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry 1992, 49:538-544.
10. Friedman J.H., Fernandez H.H. Autopsy follow-up of a patient with schizophrenia and presumed idiopathic Parkinson's disease. Clin. Neuropharmacol. 2001, 24:120-121.
11. Friedman J.H., Max J., Swift R. Idiopathic Parkinson's disease in a chronic schizophrenic patient: long-term treatment with clozapine and L-DOPA. Clin. Neuropharmacol. 1987, 10:470-475.
12. Halliday J., Farrington S., MacDonald S., MacEwan T., Sharkey V., McCreadie R. Nithsdale Schizophrenia Surveys 23: movement disorders. 20-year review. Br. J. Psychiatry 2002, 181:422-427.
13. Hassin-Baer S., Sirota P., Korczyn A.D., Treves T.A., Epstein B., Shabtai H., Martin T., Litvinjuk Y., Giladi N. Clinical characteristics of neuroleptic-induced parkinsonism. J. Neural Transm. 2001, 108:1299-1308.
14. Hausner R.S. Neuroleptic-induced parkinsonism and Parkinson's disease: differential diagnosis and treatment. J. Clin. Psychiatry 1983, 44:13-16.
15. Hoffman W.F., Labs S.M., Casey D.E. Neuroleptic-induced parkinsonism in older schizophrenics. Biol. Psychiatry 1987, 22:427-439.
16. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinic-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 1992, 55:181-184.
17. Lam R.W. Chronic schizophrenia and idiopathic Parkinson's disease. Can. J. Psychiatry 1993, 38:75-77.
18. Melamed E., Achiron A., Shapira A., Davidovicz S. Persistent and progressive parkinsonism after discontinuation of chronic neuroleptic therapy: an additional tardive syndrome?. Clin. Neuropharmacol. 1991, 14:273-278.
19. Mutch W.J., Smith W.C., Scott R.F. A screening and alerting questionnaire for parkinsonism. Neuroepidemiology 1991, 10:150-156.
20. Philibert M., Richer F., Blanchet P., Chouinard S., Dubarry A.S., Fimbel E. Movement irregularities in atypical Parkinsonian syndromes. Parkinsonism Rel. Disord. 2009, 15:542-545.
21. Pia L., Tamietto M. Unawareness in schizophrenia: neuropsychological and neuroanatomical findings. Psychiatry Clin. Neurosci. 2006, 60:531-537.
22. Rochon P.A., Stukel T.A., Sykora K., Gill S., Garfinkel S., Anderson G.M., Normand S.L.T., Mamdani M., Lee P.E., Li P., Bronskill S.E., Marras C., Gurwitz J.H. Atypical antipsychotics and parkinsonism. Arch. Intern. Med. 2005, 165:1882-1888.
23. Schwarz J., Scherer J., Trenkwalder C., Mozley P.D., Tatsch K. Reduced striatal dopaminergic innervation shown by IPT and SPECT in patients under neuroleptic treatment: need for levodopa therapy?. Psychiatry Res. Neuroimaging Sect. 1998, 83:23-28.
24. Tanner C.M., Gilley D.W., Goetz C.G. A brief screening questionnaire for parkinsonism. Ann. Neurol. 1990, 28:267-268.
25. Winter C., Juckel G., Plotkin M., Niehaus L., Kupsch A. Paranoid schizophrenia and idiopathic Parkinson's disease do coexist: a challenge for clinicians. Psychiatry Clin. Neurosci. 2006, 60:639.